CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jorge Conde

General Partner, Andreessen Horowitz

Verified interview transcripts, podcast appearances, and direct quotes from Jorge Conde, General Partner at Andreessen Horowitz. AI-verified speaker identity with full-text searchable transcripts.

Recent appearances

  • Inside Moderna’s Biggest mRNA Test Since COVID

    September 02, 2026 · 📺 a16z

    a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it…

    Watch on YouTube ↗

  • Solving Gene Therapy's Delivery Problem

    November 07, 2025 · 📺 a16z Bio & Health

    For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells. Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine…

    Watch on YouTube ↗

  • Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde

    December 12, 2023 · 📺 a16z

    Traditional drug development is like single-use rockets—costly and bespoke. But, inspired by SpaceX's rocket reusability, imagine programmable medicines that reuse components, transforming the way we innovate. General PartnerJorge Conde shares his Big Idea for 2024 and how the FDA is embracing this shift, adopting the FAA's approach to aviation safety for transparent and flexible evaluations of programmable medicines. Timecodes: 00:00 - Big Ideas in Tech 2024 01:39 - Programming Medicine’s Final Frontier 03:07 - The three stages of developing drugs in 2023 06:35 - The impact of programmable…

    Watch on YouTube ↗

  • Jorge Conde Talks About Programming Medicine

    May 15, 2023 · 📺 Wiki Plus

    What is a medicine, really? From the days of aspirin from willow bark, medicine is as old as humanity itself: something humans have been discovering, designing, and creating for ages to help heal ourselves. But now, thanks to technology, we’re entering an entirely new age where the very definition of what a medicine is, is changing. In this talk given at a16z’s annual Summit event, Jorge Conde — general partner on the bio fund at Andreessen Horowitz — talks about how we are now harnessing and even programming biology itself in new modalities, from the cell to the gene to the living microbiome.…

    Watch on YouTube ↗

  • 🧬 It’s Time to Heal — a16z on the future of bio and healthcare

    March 01, 2021 · 📺 VoiceChats.‎io

    #Clubhouse #Healthcare #Bio 🧬 It’s Time to Heal — a16z on the future of bio and healthcare Speakers: Jorge Conde, George Church, Vijay Pande, Marc Andreessen, Vineeta Agarwala, Julie Yoo It’s Time to Heal is a16z’s Clubhouse room to cover the future of bio and healthcare. Our very special guest this week is renowned Harvard Medical School geneticist George Church! 🧬🧙‍♂️ Join at https://www.joinclubhouse.com/event/M... George Church — an American geneticist, molecular engineer, and chemist. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Scien…

    Watch on YouTube ↗

  • a16z Podcast | Taking the Pulse on Bio

    January 01, 2019 · 📺 a16z

    This conversation between the members of a16z's bio team -- including general partners Jorge Conde and Vijay Pande; Malinka Walaliyadde; and Jeffrey Low (the interviewer) -- takes a quick pulse on where we are with when bio becomes more like engineering. Especially given the announcement of our second bio fund, this episode of the a16z Podcast covers everything from the broader trends at play to some specific areas of interest... as well as what types of entrepreneurs may bring us forward into the new Century of Biology.

    Watch on YouTube ↗

  • Pande & Conde on: Players and Paths for Healthcare Startups

    March 31, 2018 · 📺 a16z

    The creation of each new technology enables a tool, a therapy, or a diagnostic: a cell, a protein, even an app. But the process underneath isn't just complex in the science and engineering of it, but in the go to market. So in this video, a16z bio fund general partners Jorge Conde and Vijay Pande give a quick hallway-conversation style overview on who the stakeholders are in this process. What's the process from inception to approval to market, and how do go-to-market models differ? What should founders know at the beginning of each path? *** The views expressed here are those of the individu…

    Watch on YouTube ↗

  • Pande & Conde: When (and How) Biology Becomes Engineering

    March 23, 2018 · 📺 a16z

    Hypothesis, test, revise -- that's science. Engineering, however, doesn't quite go that way: You have parts you know and understand (like legos), and then you use those parts to design and build something (like bridges). But the key is that when science -- time-consuming, unpredictable, slow/expensive -- becomes more like engineering -- faster, more methodical/repeatable, cheaper, etc. -- you can do new things or do them in better ways. This means engineering disciplines like mechanical engineering, electrical engineering, computer science, and materials science can carry over to biology. But…

    Watch on YouTube ↗

Other executives at Andreessen Horowitz

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →